We further demonstrate that TRPV1 is expressed in liver tissue and its activation by CAP enhances PPARα, PGC-1α, and UCP2 expression, promoting fatty acid oxidation, reducing hepatic lipid burden, and inhibiting MASLD progression. The gene discussed is TRPV1; the disease is metabolic dysfunction-associated steatotic liver disease.